Stroma-Rich Co-Culture Multicellular Tumor Spheroids as a Tool for Photoactive Drugs Screening.

Fiche publication


Date publication

octobre 2019

Journal

Journal of clinical medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEZDETNAYA-BOLOTINE Lina, Pr DOLIVET Gilles, Dr LASSALLE Henri-Pierre


Tous les auteurs :
Yakavets I, Jenard S, Francois A, Maklygina Y, Loschenov V, Lassalle HP, Dolivet G, Bezdetnaya L

Résumé

Conventional 3D multicellular tumor spheroids of head and neck squamous cell carcinoma (HNSCC) consisting exclusively of cancer cells have some limitations. They are compact cell aggregates that do not interact with their extracellular milieu, thus suffering from both insufficient extracellular matrix (ECM) deposition and absence of different types of stromal cells. In order to better mimic in vivo HNSCC tumor microenvironment, we have constructed a 3D stroma-rich in vitro model of HNSCC, using cancer-associated MeWo skin fibroblasts and FaDu pharynx squamous cell carcinoma. The expression of stromal components in heterospheroids was confirmed by immunochemical staining. The generated co-culture FaDu/MeWo spheroids were applied to study penetration, distribution and antitumor efficacy of photoactive drugs such as Temoporfin and Chlorin e6 used in the photodynamic therapy flow cytometry and fluorescence microscopy techniques. We also investigated the distribution of photodiagnostic agent Indocyanine Green. We demonstrated that the presence of stroma influences the behavior of photoactive drugs in different ways: (i) No effect on Indocyanine Green distribution; (ii) lower accumulation of Chlorin e6; (iii) better penetration and PDT efficiency of Temoporfin. Overall, the developed stroma-rich spheroids enlarge the arsenal of in vitro pre-clinical models for high-throughput screening of anti-cancer drugs.

Mots clés

cancer-associated fibroblasts, drug penetration, head and neck squamous carcinoma, multicellular tumor spheroids, photodynamic therapy, temoporfin

Référence

J Clin Med. 2019 Oct 15;8(10):